Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q3 FY23 results · Oct–Dec 2022

Aurobindo Pharma reported revenue from operations of ₹6,407.13 crore (up 6.7% from Q3 FY22) and net profit of ₹491.01 crore (down 18.7% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	6,407.13	6,002.22	+6.7%	5,739.37	+11.6%
Other income	92.65	64.99	+42.6%	57.19	+62.0%
Total income	6,499.78	6,067.21	+7.1%	5,796.56	+12.1%
Profit before share of associates & JVs and tax	680.70	800.87	−15.0%	524.59	+29.8%
Share of profit/(loss) of associates & JVs	(0.59)	(7.09)		(1.23)
Net profit for the period	491.01	604.29	−18.7%	410.37	+19.7%
Attributable to shareholders of the company	491.26	546.55	−10.1%	409.45	+20.0%
EPS, basic (₹)	8.38	10.32	−18.8%	6.99	+19.9%
Net margin (%)	7.7	10.1		7.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	3,432.26	2,623.05	+30.8%	3,025.66	+13.4%
Other income	78.73	131.29	−40.0%	55.86	+40.9%
Total income	3,510.99	2,754.34	+27.5%	3,081.52	+13.9%
Profit before tax	404.49	242.46	+66.8%	223.76	+80.8%
Net profit for the period	298.82	239.81	+24.6%	164.63	+81.5%
EPS, basic (₹)	5.10	4.09	+24.7%	2.81	+81.5%
Net margin (%)	8.7	9.1		5.4

Consolidated

Filed with BSE: 10 Feb 2023, 15:14 IST
Board meeting: 09 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 10 Feb 2023, 15:14 IST
Board meeting: 09 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE